• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, September 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Older women have the highest risk of dying from cervical cancer

Bioengineer by Bioengineer
April 3, 2019
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New research from Aarhus University and Aarhus University Hospital shows that women aged 65 and older have a higher risk of dying from cervical cancer than previously thought — although this age group is not covered by the Danish screening program

Denmark has one of highest incidences of cervical cancer in the Western world. But once a person has turned 65, they are no longer automatically screened – even though older women are in fact those who have the highest mortality. This is shown by new research from Aarhus University and Aarhus University Hospital.

“Cervical cancer has become known as ‘a young women’s disease’. But it’s a myth that it only affects young people. In fact, the mortality rate among women above the age of 65 is 25-30 per cent higher than previously thought,” says medical doctor and postdoc Anne Hammer from the Department of Clinical Medicine, Aarhus University and Aarhus University Hospital.

She is behind the new study which has just been published in the scientific journal Acta Obstetricia et Gynecologica Scandinavia. The researchers looked at cervical cancer mortality rates in Denmark between 2002-2015 and found that the over 65s stood out here. For example, the mortality rate was five times higher among woman aged 75-79 compared to those aged 40-45.

Advanced cancer

The research results support a study from November 2018 in which Anne Hammer and her research colleagues found that older women were very often diagnosed so late that the cancer was already too big to be surgically removed. In such cases patients are instead treated with radiotherapy and chemotherapy – a treatment that is associated with side effects such as pain and urination and defecation discomfort.

More than half of the older women with cervical cancer who had followed the screening programme on a regular basis until it expired are diagnosed with cancer that is so advanced that surgery is no longer possible.

“When people are screened, the cancer can be discovered in its initial stages or at such an early stage that surgical treatment is still possible. This significantly reduces the risk of dying,” says Anne Hammer.

Older women should also be screened

With the current rules, the screening programme stops if a person is tested negative between the ages of 60-64. According to Anne Hammer, there are plenty of grounds – especially with the new studies – to introduce initiatives to reduce the incidences and mortality from cervical cancer. This could for example be done by extending the screening programme.

“The negative test does not guarantee that someone won’t get the disease after the screening ends, because the HPV virus which is the cause of the cancer can lie dormant in the body,” says Anne Hammer. She also points out that there will very likely be fewer young women with cervical cancer in 5-10 years’ time due to the HPV vaccine.

“But it will take many years before we see an effect among older women. When the society you live in has such a high incidence of advanced cervical cancer among older women with such a high mortality rate, then it is important to explore which interventions should be initiated to reverse this trend,” says Anne Hammer, before adding that as long as the screening programme is not extended, the only thing to do is to keep a close eye on symptoms such as bleeding and altered discharge.

###

The research results – more information

Type of study: Danish register-based study

Partners: Johnny Kahlert, PhD, Department of Clinical Epidemiology, AUH and Assistant Professor, PhD, Anne Rositch, Johns Hopkins Bloomberg School of Public Health, USA.

Media Contact
Anne Hammer
[email protected]
http://dx.doi.org/10.1111/aogs.13608

Tags: cancerGynecologyMedicine/Health
Share13Tweet8Share2ShareShareShare2

Related Posts

Sex Differences in Alcohol’s Impact on Brain Dopamine

September 6, 2025

Fecal Transplants: New Hope for Alzheimer’s Treatment

September 6, 2025

CheckMate 77T: Nivolumab Preserves Quality of Life and Mitigates Symptom Worsening in Resectable NSCLC

September 6, 2025

miR-BART19-3p Boosts EBV-Associated Gastric Cancer Growth

September 6, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    54 shares
    Share 22 Tweet 14

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Phase II Study Finds Iza-Bren Plus Osimertinib Achieves 100% Response Rate in EGFR-Mutated NSCLC

Novel Antibody-Drug Conjugate Demonstrates Promising Efficacy in EGFR-Mutated NSCLC Patients

COMPEL Study Finds Adding Chemotherapy to Osimertinib After Progression Enhances Progression-Free Survival in EGFR-Mutated NSCLC

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.